USP2 and neoplasm: Thus, targeting the USP2/VPRBP pathway unleashes the latent tumor suppression activity of p53 in cancer cells, avoids the severe toxicities associated with Mdm2 inhibitors, and synergizes effectively with immune checkpoint blockade to achieve dramatic tumor regression in vivo.